US Patent

US8802735 — (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability

Formulation · Assigned to Sanofi SA · Expires 2030-09-14 · 4y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects tablet formulations of a specific amide compound, used to treat autoimmune diseases such as multiple sclerosis.

USPTO Abstract

The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.

Drugs covered by this patent

Patent Metadata

Patent number
US8802735
Jurisdiction
US
Classification
Formulation
Expires
2030-09-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.